Mateusz Kaczmarek

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets. Follow Mateusz Kaczmarek on Google News.

Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys, Inc. is ending the week with fresh analyst attention after posting a stronger‑than‑expected third quarter and raising full‑year guidance earlier this week. As of today, one outlet reports an upgrade to Buy while another highlights lifted EPS forecasts, keeping the cybersecurity name on radar for Google News and Discover readers tracking post‑earnings momentum. The shares are trading around the $150 mark. MarketBeat+1
8 November 2025
··
CAVA Stock News Today (Nov 8, 2025): Guidance Cut Fallout, Analyst Target Resets, and What’s Next for CAVA Group (NYSE: CAVA)

CAVA Stock News Today (Nov 8, 2025): Guidance Cut Fallout, Analyst Target Resets, and What’s Next for CAVA Group (NYSE: CAVA)

CAVA’s long runway remains intact, but near‑term comps are caught in a consumer downdraft affecting much of fast casual. Management’s choice to protect brand equity—rather than chase discount traffic—means investors will be watching Q4 trends closely to see if loyalty, menu news and operational tweaks can re‑accelerate visits without sacrificing margins. Business Insider+1
8 November 2025
·
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters
8 November 2025
···
EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build

EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build

Eos Energy Enterprises, Inc. closed out a whipsaw week with fresh weekend headlines: an analyst downgrade, a small fund trimming its position, and continued attention on the company’s Q3 results and growing long‑duration storage pipeline. Below is a concise roundup of what’s new today, plus the key numbers and catalysts investors are watching from this week’s earnings, contracts, and financing updates.
8 November 2025
·
Today in Airline Routes (Nov. 8, 2025): Breeze enters Twin Falls; JetBlue targets Destin–Fort Walton; Spirit lands in Key West — plus key global moves

Today in Airline Routes (Nov. 8, 2025): Breeze enters Twin Falls; JetBlue targets Destin–Fort Walton; Spirit lands in Key West — plus key global moves

Breeze Airways is continuing its “underserved markets” strategy with a fresh round of growth for spring 2026 — and a brand‑new dot on its map: Twin Falls, Idaho. Starting March 6, 2026, Breeze will fly nonstop Twin Falls–Las Vegas and offer a same‑plane “BreezeThru” to Orange County on the same days. The expansion also brings:
8 November 2025
Conduent (CNDT) Q3 2025 Earnings: Revenue Misses at $767M as Adjusted EBITDA Margin Climbs to 5.2%; FY 2025 Margin Outlook 5.0%–5.5%, Shares Slide

Conduent (CNDT) Q3 2025 Earnings: Revenue Misses at $767M as Adjusted EBITDA Margin Climbs to 5.2%; FY 2025 Margin Outlook 5.0%–5.5%, Shares Slide

Conduent Incorporated reported third‑quarter 2025 revenue of $767 million and Adjusted EBITDA of $40 million with a 5.2% margin, reflecting continued cost discipline even as top‑line pressure persisted. Management reiterated a full‑year 2025 Adjusted EBITDA margin outlook of 5.0%–5.5% alongside Adjusted Revenue guidance of $3.05–$3.10 billion. The stock fell sharply following the release. GlobeNewswire+1
8 November 2025
··
VTI vs. VOO on November 7, 2025: Daily Update, Flows & Why Vanguard’s Flagship ETFs Still Dominate With Young Investors

VTI vs. VOO on November 7, 2025: Daily Update, Flows & Why Vanguard’s Flagship ETFs Still Dominate With Young Investors

Fresh data from TipRanks’ “VTI ETF Daily Update — 11/7/2025” shows the Vanguard Total Stock Market ETF slipped 1.17% on Thursday, part of a −2.72% five‑day stretch, while YTD returns remain +14.71%. Despite choppy price action, investors added $382M to VTI over the last five trading days, and the fund still trades above its 50‑day EMA, a constructive near‑term technical backdrop. TipRanks
7 November 2025
·····
Franklin Resources (BEN) Q4 FY2025: Adj. EPS $0.67 Beats, Revenue $2.34B; AUM $1.66T as Ex‑Western Inflows Climb

Franklin Resources (BEN) Q4 FY2025: Adj. EPS $0.67 Beats, Revenue $2.34B; AUM $1.66T as Ex‑Western Inflows Climb

Franklin Resources, Inc., the parent of Franklin Templeton, reported preliminary fiscal Q4 2025 results before the bell Friday, posting GAAP revenue of $2.34 billion and adjusted diluted EPS of $0.67, topping pre‑earnings consensus that had centered around $0.57 EPS and $2.12 billion in revenue. Quarter‑end assets under management were $1.66 trillion. The firm recorded long‑term net outflows of $11.9 billion, but net inflows of $11.4 billion excluding Western Asset Management, and highlighted a won‑but‑unfunded institutional pipeline of $20.4 billion. Nasdaq+3investors.franklinresources.com+3investors.franklinresources.com+3
7 November 2025
·
AMD Today: 2nm ‘Venice’ CPUs & MI400 AI Accelerators Confirmed for 2026 as Shares Flicker Ahead of Nov. 11 Analyst Day

AMD Today: 2nm ‘Venice’ CPUs & MI400 AI Accelerators Confirmed for 2026 as Shares Flicker Ahead of Nov. 11 Analyst Day

Advanced Micro Devices, Inc. headlines today with fresh confirmation that its next big data‑center leap—2nm “Epyc Venice” CPUs and Instinct MI400 accelerators—is slated for 2026, while investors count down to AMD’s Financial Analyst Day on Tuesday, November 11. The stock softened intraday as markets digested this week’s record Q3 print and looked for the next catalyst. TechSpot+1
7 November 2025
·
Ford (F) Today — Nov. 7, 2025: Lightning Cancellation Report, Ex‑Dividend Trading, and Recall Mailings Shape the Narrative

Ford (F) Today — Nov. 7, 2025: Lightning Cancellation Report, Ex‑Dividend Trading, and Recall Mailings Shape the Narrative

A Wall Street Journal story says Ford executives are considering scrapping the F‑150 Lightning, the brand’s flagship battery‑electric pickup. Ford declined to confirm the move, noting it has inventory on hand and will bring the Rouge Electric Vehicle Center back up “at the right time,” without giving a restart date. The pause traces to a September fire at aluminum supplier Novelis, which constrained body‑panel metal for F‑Series. Reuters
7 November 2025
·
Crypto Markets Today (Nov 7, 2025): ‘Extreme Fear’ Lingers as ETFs Snap Outflow Streak; Research Confirms First Red October Since 2018

Crypto Markets Today (Nov 7, 2025): ‘Extreme Fear’ Lingers as ETFs Snap Outflow Streak; Research Confirms First Red October Since 2018

Crypto sentiment remains fragile to end the week, but there are early signs of stabilization after days of risk-off trading. A key sentiment gauge has swung to “Extreme Fear”, while spot crypto ETFs notched fresh inflows on Thursday, Nov. 6, breaking a six‑day outflow streak. Meanwhile, new research confirms October 2025 was the first “red October” for crypto since 2018, following last month’s record liquidation event. Alternative.me+2Moneyweb+2
7 November 2025
···
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran, its in vivo CRISPR therapy for transthyretin amyloidosis. The FDA’s clinical holds on MAGNITUDE and MAGNITUDE‑2 are still in effect pending a formal hold letter. GlobeNewswire+1
7 November 2025
···
1 … 61 62 63 64 65 … 164

Stock Market Today

  • Morgan Stanley Lifts GE Vernova (GEV) Price Target to $1,350, Reiterates Overweight
    July 25, 2026, 9:25 PM EDT. Morgan Stanley has increased its price target for GE Vernova (NYSE: GEV) to $1,350 from $1,250 while keeping an Overweight rating, anticipating a 30.51% upside potential. Following GE Vernova's July 22 earnings release, which reported $11.10 billion revenue surpassing forecasts and robust profitability metrics despite an EPS miss, analysts from RBC Capital, Oppenheimer, and Guggenheim also raised their targets.